API CAS 1038915-60-4 Niraparib Intermediate Niraparib Tosylate Monohydrate Powder Niraparib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Niraparib
• Product Name: Niraparib
• Name: Niraparib Powder
• Appearance: off-White Crystalline Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anticancer
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 1038915-60-4
• Mf: C19h20n4o
• MW: 320.3883
• Density: 1.343
• Boiling Point: 463.619 C at 760 Mmhg
• Refractive Index: 1.705
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500 Kg/Month

Product Description

API CAS 1038915-60-4 Niraparib Intermediate Niraparib Tosylate Monohydrate Powder Niraparib

 

Product Description

Product Details

Product Name	Niraparib
Appearance	Off-white crystalline powder
CAS No.	1038915-60-4
MF	C19H20N4O
MW	320.3883

Nilaparib is a polyadenosine diphosphate ribose polymerase inhibitor, which inhibits DNA repair.   Its active component is free alkali, stable composition is a molecule containing water of crystallization of p-toluene sulfonic acid salt or effective component for niraparibtosylatemonohydrate hydrochloride.  Niraparib is a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian,fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Application & Function

Function of Niraparib
Niraparib is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer.
The drug is approved by the US FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Application of Niraparib
It is mainly used for the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and maintenance treatment of adult patients who have fully or partially responded to platinum chemotherapy drugs.

Specification